SSY Group Limited

2005

KYG8406X1034

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:10 26/06/2024 BST			5-day change	1st Jan Change
4.33 ^HKD	-0.23%		-8.84%	-12.35%

06-23	SSY Group Limited Announces Update on Product Development	CI
06-18	SSY’s Hypertension Drug Passes Chinese Regulator’s Consistency Eval; Obtains Go-Ahead for Production, Registration	MT

Lijun International Pharmaceutical Co Ltd. Resignation of Zhang Guifu as Executive Director, Effective from 5 April 2012

April 05, 2012 at 04:23 pm

Lijun International Pharmaceutical (Holding) Co Ltd. announced that Ms. Zhang Guifu has resigned as an executive director of the company with effect from 5 April 2012 in order to devote more time to her other business commitments.

Latest news about SSY Group Limited

SSY Group Limited Announces Update on Product Development	06-23	CI
SSY’s Hypertension Drug Passes Chinese Regulator’s Consistency Eval; Obtains Go-Ahead for Production, Registration	06-18	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China	06-18	CI
SSY Group Gets Bulk Drug Registration Go-Ahead for Ischemic Stroke Drug in China	06-10	MT
SSY Group Limited Announces Update on Product Development	06-07	CI
SSY Group Limited Announces that the Group Has Obtained the Approval for Drug Production and Registration for Entacapone Tablets (0.2G)	06-03	CI
SSY Group Gets Chinese Regulator’s Approval for Drug Production, Registration	06-03	MT
Ssy Group Limited Announces that the Group has Obtained the Approval for Drug Production and Registration for Bisoprolol Fumarate and Amlodipine Besilate Tablets	06-03	CI
SSY Group's Trelagliptin Succinate Gets Bulk Drug Approval in China	05-30	MT
SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China	05-30	CI
SSY Group’s Dialysis Solution Passes Generic Drug Evaluation in China	05-30	MT
SSY Group Limited Provides Update on Product Development	05-30	CI
SSY Obtains China Approval for Additional Specification, Generic Status of Metabolic Acidosis Drug	05-28	MT
SSY Group Limited Announces Update on Product Development	05-28	CI
SSY Group Gets China Approval for Chemotherapy-Induced Nausea Treatment	05-27	MT
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China	05-27	CI
SSY Group’s Bronchitis Drug Gets Registration Approval in China	05-22	MT
Ssy Group Limited Announces That the Group's Formoterol Fumarate Has Obtained the Approval for Registration from the National Medical Products Administration	05-22	CI
SSY Group Gets Production and Registration Approval for Parkinson’s Disease Drug in China	05-21	MT
Ssy Group Limited Announces That the Group Has Obtained the Approval for Drug Production and Registration for Rasagiline Mesylate Tablets from National Medical Products Administration of China	05-21	CI
SSY Group’s Multiple Electrolytes Injection Passes Chinese Regulator’s Consistency Evaluation	05-13	MT
SSY Group Limited Announces Approval for National Medical Products Administration of China for the Passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Multiple Electrolytes Injection	05-13	CI
SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	04-23	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Linezolid for Oral Suspension	04-23	CI
SSY Group Logs Nearly 15% Boost in Q1 Profit	04-16	MT

Chart SSY Group Limited

Duration

Period

More charts

Company Profile

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Companyâs main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Companyâs products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Companyâs products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Sector

Pharmaceuticals

Calendar

25/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for SSY Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.33 HKD

Average target price

6.227 HKD

Spread / Average Target

+43.80%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SSY GROUP LIMITED	-12.35%	1.65B
ELI LILLY AND COMPANY	+54.42%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.42%	354B
MERCK & CO., INC.	+21.56%	337B
ABBVIE INC.	+10.78%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+8.61%	171B

Other Pharmaceuticals

SSY Group Limited

Equities

2005

KYG8406X1034

Pharmaceuticals

Lijun International Pharmaceutical Co Ltd. Resignation of Zhang Guifu as Executive Director, Effective from 5 April 2012

Latest news about SSY Group Limited

Chart SSY Group Limited

Company Profile

Income Statement Evolution

Ratings for SSY Group Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals